Tempest Therapeutics, Inc.
TPST-1495
Familial Adenomatous Polyposis
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for TPST-1495 in Familial Adenomatous Polyposis are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Initiate a Phase 2 study of TPST-1495 in FAP, with first patient enrollment expected in 2026”